Ernesto Korbenfeld
-
- Cancer Immunotherapy and Biomarkers 6
- HER2/EGFR in Cancer Research 5
- Cancer Treatment and Pharmacology 4
- PARP inhibition in cancer therapy 4
- Colorectal Cancer Treatments and Studies 3
-
- Prostate Cancer Treatment and Research 6
- Advanced Breast Cancer Therapies 3
- Renal cell carcinoma treatment 3
- Co-authors
- Enriqueta FelipSeema SethiHidetoshi HayashiAdlinda AlipJoshua BaumlPongwut DanchaivijitrAlexander I. SpiraJosiane Mourão Dias
- Journals
- Journal of Clinical Oncology (4 papers)Cancer Research (1 paper)Annals of Oncology (4 papers)
- Partner nations
- ArgentinaUnited StatesFrance
In The Last Decade
Ernesto Korbenfeld
24 papers receiving 180 citations
Peers
Comparison fields: 5 of 32
- Oncology 113
- Pulmonary and Respiratory Medicine 133
- Cancer Research 50
- Internal Medicine 3
- Immunology 16
Countries citing papers authored by Ernesto Korbenfeld
This map shows the geographic impact of Ernesto Korbenfeld's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ernesto Korbenfeld with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ernesto Korbenfeld more than expected).
Fields of papers citing papers by Ernesto Korbenfeld
This network shows the impact of papers produced by Ernesto Korbenfeld. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ernesto Korbenfeld. The network helps show where Ernesto Korbenfeld may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Ernesto Korbenfeld, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 14 | |
| 2 | 2025 | 0 | |
| 3 | 2025 | 1 | |
| 4 | 2024 | 1 | |
| 5 | 2024 | 8 | |
| 6 | 2024 | 2 | |
| 7 | 2024 | 7 | |
| 8 | 2024 | 0 | |
| 9 | 2023 | 1 | |
| 10 | 2023 | 1 | |
| 11 | 2023 | 3 | |
| 12 | 2023 | 24 | |
| 13 | 2023 | 47 | |
| 14 | 2021 | 3 | |
| 15 | 2021 | 15 | |
| 16 | 2021 | 2 | |
| 17 | 2016 | 1 | |
| 18 | 2014 | 27 | |
| 19 | 2013 | 2 | |
| 20 | 2006 | 6 |
About Ernesto Korbenfeld
Ernesto Korbenfeld is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 28 papers that have together received 182 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (6 papers), Prostate Cancer Treatment and Research (6 papers), HER2/EGFR in Cancer Research (5 papers), Cancer Treatment and Pharmacology (4 papers), PARP inhibition in cancer therapy (4 papers), Advanced Breast Cancer Therapies (3 papers), Renal cell carcinoma treatment (3 papers) and Colorectal Cancer Treatments and Studies (3 papers). The work is most often cited by research in Oncology (113 citations), Pulmonary and Respiratory Medicine (133 citations) and Cancer Research (50 citations). Ernesto Korbenfeld has collaborated with scholars based in Argentina, United States and France. Frequent co-authors include Enriqueta Felip, Seema Sethi, Hidetoshi Hayashi, Adlinda Alip, Joshua Bauml, Pongwut Danchaivijitr, Alexander I. Spira, Josiane Mourão Dias, SH Lee and Nicolai Leonhartsberger. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.